Vyome Holdings, Inc. (NASDAQ:HIND) Short Interest Down 38.2% in March

Vyome Holdings, Inc. (NASDAQ:HIND) saw a large decline in short interest in the month of March. As of March 13th, there was short interest totaling 128,513 shares, a decline of 38.2% from the February 26th total of 208,107 shares. Currently, 2.7% of the shares of the company are sold short. Based on an average daily volume of 50,637 shares, the days-to-cover ratio is currently 2.5 days.

Vyome Stock Down 2.5%

NASDAQ HIND traded down $0.06 during trading on Friday, hitting $2.15. 13,913 shares of the company’s stock traded hands, compared to its average volume of 899,619. The stock has a market capitalization of $15.06 million, a PE ratio of -0.02 and a beta of 1.34. Vyome has a 12-month low of $1.75 and a 12-month high of $305.00. The business’s 50 day simple moving average is $2.65.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e-)” rating on shares of Vyome in a research note on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $15.00.

Institutional Trading of Vyome

An institutional investor recently bought a new position in Vyome stock. Geode Capital Management LLC purchased a new position in Vyome Holdings, Inc. (NASDAQ:HIND) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 11,934 shares of the company’s stock, valued at approximately $41,000. Geode Capital Management LLC owned 0.21% of Vyome as of its most recent filing with the Securities and Exchange Commission (SEC). 22.06% of the stock is currently owned by institutional investors.

About Vyome

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.